Is There a Benefit to Optimize Heart Failure (HF) Treatment in Aged Over 80 Year's Old Patients?

• Status: Completed
• Trial end date: 2014-06-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine if there is an interest to optimize HF (heart failure) management in patients over 80 years old. The primary objective is to assess the effect of HF (heart failure) optimized management (guidelines of the European society of Cardiology (ESC) on Quality of Life (QOL) in aged over 80 year's old at 6 months.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University Hospital, Clermont-Ferrand
• Collaborators: LivaNova; Servier
• Treatments: Captopril; Enalapril; Enzyme Inhibitors; Lisinopril; Ramipril; Trandolapril

Criteria

Inclusion Criteria:

• Aged over 80 year's old subjects

• Hospitalized for an acute heart failure

• Left Ventricle Ejection Fraction ≤ 35%

• Evaluated life expectancy (Seattle HF score) > 1 year

Exclusion Criteria:

• Dementia

• Does not understand French language

• Followed with an optimized management

• With reduced mobility

• Recruited in another clinical trial or in a HF management network

• AHF with curable aetiology : cardiovascular surgery for CABG or valvular replacement, angioplasty

• MDRD < 30 ml/min/1.73m²